Achieving high-precision personalized cancer therapy with multimodal nano imaging agents; lead application in image-guided surgery.
Focus: Medical Devices & Diagnostics Commencement date: June, 2017 Location:JLABS @ Toronto
Personalized cancer therapy requires that doctors precisely localize the tumor throughout the course of therapy in order to eradicate it. Nanovista, Inc.’s proprietary imaging agent platform leverages nanotechnology to provide continued visibility of the malignant tumor tissue before, during and after surgery. Our nano agent has the potential to significantly improve the precision of over 200 million cancer surgery procedures conducted each year around the world.
As cancer diagnosis and screening improve, surgeons have the challenge of having to resect increasingly small tumors that are often invisible and non-palpable. Attempts that have tried to address this challenge relied on either implanting invasive objects to mark the location of the tumor or using non-specific imaging agents to provide some transient visibility requiring the patient to be injected and scanned multiple times over the course of the surgery. Nanovista’s technology enables effective tumor visualization using multiple imaging modalities following a single administration over the entire course of surgery from pre-operative planning to intra-operative guidance and post-operative assessment.
Nanovista’s passion is fueled by a desire to help a high potential technology that has produced great results in its laboratories to reach clinical use and ultimately provide concrete benefits to cancer patients worldwide.